Effect of IL-7 on Th17 cell responses in a mouse model of neutrophilic asthma

XIAOBO ZHANG1*, MIN ZHANG2*, MIN JIANG1 and GUANGMIN NONG1

1Pediatric Department, First Affiliated Hospital of Guangxi Medical University, Nanning; 2Pediatric Department, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China

Received July 04, 2019; Accepted April 21, 2020

DOI: 10.3892/mmr.2020.11191

Abstract. Neutrophilic asthma (NA) is characterized by neutrophil-mediated inflammation and the presence of Th17 cells. However, the mechanisms underlying Th17 cell responses in NA remain unknown. The aim of the present study was to examine the effects of interleukin (IL)-7 on Th17 cell responses in NA. A NA mouse model was sensitized by airway delivery of ovalbumin (OVA) and lipopolysaccharide and challenged with 1% OVA aerosol from day 21 for 3 consecutive days. Airway resistance was then measured to assess airway hyper-responsiveness (AHR). Cells from bronchoalveolar lavage fluid (BALF) underwent Diff-Quick and hematoxylin and eosin staining for classification. The levels of IL-17 in the BALF were determined by ELISA. The effects of IL-7 administration and STAT5 inhibition on Th17 cells were also characterized in vitro using splenic CD4+ T cells. Ki-67, Bcl-2 and activated caspase-3 expression in differentiated Th17 cells were analyzed by flow cytometry. The mouse model of NA was characterized by increased AHR, elevated levels of IL-17, high neutrophil counts in BALF, accumulated inflammatory cells in the lung and Th17 cell responses. IL-7 promoted the expression of Ki-67 and Bcl-2 while reducing caspase-3 expression. STAT5 inhibitor treatment decreased the levels of Ki-67 and Bcl-2, and resulted in increased expression of caspase-3. These results suggested that the IL-7/JAK/STAT5 signaling pathway may be involved in Th17 cell responses in NA.

Introduction

Asthma is a common chronic airway inflammatory disease with two subtypes, eosinophilic asthma and non-eosinophilic asthma. Neutrophilic asthma (NA) accounts for more than one-half of non-eosinophilic asthma (1-3). Corticosteroid treatment is effective for most patients with mild and moderate asthma. However, patients with NA require a high dose of corticosteroids for symptom control (4). An in-depth understanding of the mechanisms underlying NA would provide insight into therapeutic options for this condition.

Our previous studies (Jiang et al., unpublished data) demonstrated that Th17 cells were dominant and promoted neutrophil-mediated airway inflammation through interleukin (IL)-17 in a mouse model of NA. The elevated IL-6 and transforming growth factor-β levels in NA model mice broncho-alveolar lavage fluid (BALF) were discovered to participate in the Th17-mediated response through regulating the expression levels of retinoic acid receptor-related orphan receptor-γt (RORγt) and suppressor of cytokine signaling 3. In addition, the increase in Th17 cells and RORγt expression in the peripheral blood, as well as upregulated sputum IL-17 levels, in children with NA were also verified. Moreover, the expression levels of phosphorylated (p)-STAT5 and Bcl-2 in Th17 cells and IL-7 levels in BALF were increased (Jiang et al., unpublished data). However, the effect of IL-7 on Th17 cells in NA remains unclear. It is known that IL-7 plays a critical role in proliferation, survival and differentiation of T lymphocytes. Indeed, IL-7 activates the JAK/STAT signaling pathway, thereby promoting T cell survival by upregulating the expression of the anti-apoptotic protein Bcl-2 (5-8). Therefore, it was hypothesized that the IL-7/JAK/STAT5 signaling pathway might also be involved in Th17 cell responses in NA.

Materials and methods

Experimental animals. A total of 12 female C57BL/6 mice (age, 6-8 weeks; weight, 18-20 g) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. and randomly divided into two groups (n=6 in each group), NA group and normal control (NC) group. Mice were housed under specific pathogen-free conditions in separate cages at a relatively stable temperature of 20-24°C and a humidity of 55±10%, with a 12-h light/dark cycle and free access to food and water. All experimental
animal protocols were approved by The Ethics Committee of The First Affiliated Hospital of Guangxi Medical University [2019 (KY-E-035)].

**Mouse model of NA.** The model used in the present study was established according to the protocol by Wilson et al (9). Mice were sensitized by airway delivery of 100 µg ovalbumin (OVA; Grade II & V; Sigma-Aldrich; Merck KGaA) and 0.1 µg lipopolysaccharide (LPS; Sigma-Aldrich; Merck KGaA) in a total volume of 50 µl PBS on days 0, 6 and 13. The OVA + LPS mixture was instilled along the posterior oropharyngeal wall, and the mixed solution was inhaled into the airway, followed by a challenge with 1% OVA aerosol for 1 h from day 21 for 3 consecutive days. The NC group received PBS treatment instead of OVA + LPS for sensitization and challenge.

**Measurement of airway hyper-responsiveness (AHR).** Airway responses to aerosolized methacholine were measured using a lung function test instrument for mouse (FinePointe Resistance and Compliance; Data Sciences International; Harbor BioSciences, Inc.). Mice were anesthetized with 1% pentobarbital sodium (50 mg/kg body weight) by intraperitoneal injection, and the trachea was cannulated with a needle, followed by mechanical ventilation. Airway resistance (R; cmH2O.s/ml) was measured after aerosolization of 10 µl PBS and administration of increasing doses of aerosolized methacholine (3.125, 6.25, 12.5, 25 and 50 mg/ml in 10 µl; Sigma-Aldrich; Merck KGaA) sequentially. The results are presented as fold-increase of R (cmH2O.s/ml) above the baseline and were calculated as follows: \[
\frac{R_{\text{response}} - R_{\text{baseline}}}{R_{\text{baseline}}} \]

**Cell classification of BALF.** Mice were sacrificed 24 h after the final aerosolization. Cervical dislocation was used for euthanasia and death was confirmed by the onset of rigor mortis, according to The National Institutes of Health Guide for the Care and Use of Laboratory Animals. The trachea was exposed, and a 22-gauge needle was used for endotracheal intubation. The lungs were subjected to broncho-alveolar lavage twice with 0.5 ml PBS (recovery rate ≥80%) and the total volume of BALF was 0.8 ml. Total and differential cell counts from BALF were determined by staining with Diff-Quick (Beijing Solarbio Science & Technology Co., Ltd.) for 1 min at room temperature. BALF was centrifuged at 160 x g for 10 min at 4°C and the supernatants were stored at -20°C for further experiments.

**Histopathology.** Lungs were fixed in 4% paraformaldehyde solution for 24 h at room temperature and subjected to gradient alcohol dehydration and paraffin-embedding, which were cut into 5-7-µm thick sections. The sections were subsequently stained with hematoxylin at room temperature for 2-3 min and then with eosin at room temperature for 30-60 sec. An Olympus CX31 light microscope (Olympus Corporation) was used to evaluate the general inflammation and the airway morphology (magnification, x200).

**ELISA.** An ELISA kit (cat. no. ELM-IL17-1; RayBiotech Life) was used to measure the levels of IL-17 in the BALF, according to the manufacturer's protocol.

**Immunomagnetic bead separation of CD4+ T cells from splenic mononuclear cells.** CD4+ T cells were purified using a magnetic separation kit (Dynal; Thermo Fisher Scientific, Inc.). Splenic mononuclear cells from mice were mixed with the supplied antibody (20 µl/107 cells), followed by inactivated fetal bovine serum (Wisent, Inc.; 20 µl/107 cells). The reaction was mixed thoroughly and incubated for 20 min at 4°C. After centrifugation at 211 x g for 5 min at 4°C, the cells were resuspended in cold PBS (800 µl/107 cells), followed by magnetic beads and incubation for 15 min at room temperature. The system was placed in the automated cell selector for 2 min to collect the supernatant containing purified CD4+ T cells, then centrifuged at 211 x g for 8 min at 4°C. The cells were resuspended at a density of 1.5x106 cells/ml, and 100 µl of this solution was incubated with PerCP-Cy™ 5.5-labeled anti-mouse CD4 monoclonal antibody (BD Biosciences; cat. no. 550954) at room temperature for 20 min. Finally, the cells were washed with PBS before fixation with 1% paraformaldehyde for 10-20 min at 4°C. Cell purity was then assessed by flow cytometry (to determine whether purity was >91%).

**Culture of mouse splenic CD4+ T cells.** Anti-CD3 (BD Biosciences; cat. no. 561798) and anti-CD28 (BD Biosciences; cat. no. 562764) antibodies were coated in each well on day 1, followed by addition of anti-IFN (BD Biosciences; cat. no. 551506) and anti-IL-4 (BD Biosciences; cat. no. 555090). Purified CD4+ T cells were seeded into a 24-well plate at a density of 1.5x106 cell per well in a 1 ml volume. Subsequently, 10 ng/ml IL-7 (PeproTech, Inc.) and 100 µM STAT5 inhibitor (Merck KGaA) were added to the culture, and incubated for 72 h. The following culture groups were obtained: Negative control (NC) group, anti-CD3 + anti-CD28 + DMSO; NC + IL-7 group, anti-CD3 + anti-CD28 + IL-7 + DMSO; NA group, anti-CD3 + anti-CD28 + DMSO; NA + IL-7 group, anti-CD3 + anti-CD28 + IL-7 + DMSO; NA + IL-7 + STAT5 inhibitor group; anti-CD3 + anti-CD28 + IL-7 + STAT5 inhibitor. The cells in each group were detected by a flow cytometry (FACS Calibur; BD Biosciences) and analyzed using FlowJo 7.6.5 software (FlowJo LLC).

**Flow cytometric analysis.** Briefly, cells from the spleen were stimulated in a complete medium with 50 ng/ml phorbol myristate acetate and 1 µg/ml ionomycin (both from...
Sigma-Aldrich; Merck KGaA) at 37˚C in 5% CO₂ for 5 h. The cells were washed with PBS and stained with surface PerCP-Cy™ 5.5 anti-mouse CD4 antibody (cat. no. 550954; clone, RM4-5; BD Biosciences) at room temperature in the dark for 30 min. Intracellular staining for p-STAT5 and IL-17A was subsequently performed; briefly, the cells were fixed at 37˚C for 10 min using warm BD Phosflow™ Fix Buffer I (cat. no. 557870; BD Biosciences) and washed with PBS. Subsequently, the cells were permeabilized for 30 min at 4˚C using the BD Phosflow™ Perm Buffer III (cat. no. 558050; BD Biosciences), washed with PBS and stained with BD Phosflow™ Alexa Fluor® 488 Anti-p-STAT5 (Y694; cat. no. 612598; clone, 47/Stat5 (pY694); BD Biosciences), BD Pharmingen™ phycoerythrin (PE) anti-mouse IL-17A (cat. no. 559502; clone, TC11-18H1; BD Biosciences) or with its isotypic control antibody for 50 min at 4˚C. Intracellular staining for IL-17A, active caspase-3, Ki-67 and Bcl-2 was also performed. Briefly, the cells were fixed and permeabilized for 30 min at 4˚C using the CytoFix/CytoPerm kit (cat. no. 554714; BD Biosciences), washed with PBS and stained with PE anti-mouse IL-17A (cat. no. 559502; clone, TC11-18H1; BD Biosciences), BD Transduction Laboratories™ FITC mouse anti-Ki-67 (cat. no. 612472; clone, 35/Ki-67; BD Biosciences), BD Pharmingen™ FITC rabbit anti-active caspase-3 (cat. no. 560901; clone, C92-605; BD Biosciences), BD Pharmingen™ FITC hamster anti-mouse Bcl-2 (cat. no. 556357; BD Biosciences) or with its isotypic control antibody for 50 min at 4˚C. Live lymphocytes were gated according to forward and side scatter, then by CD4 expression. BD Pharmingen™ PE-Cy™5 mouse IgG1 isotype control (cat. no. 550618; clone, MOPC-31C; BD Biosciences) was used as the isotype control. According to this gating strategy, CD4⁺ cells were considered helper T (Th) cells; CD4⁺IL-17⁺ cells were defined as Th17 cells. Ki-67, caspase-3 and Bcl-2 expression in Th17 cells were measured as described. Cells were detected by a flow cytometer (FACS Calibur; BD Biosciences) and analyzed using FlowJo 7.6.5 software (FlowJo LLC).

Statistical analysis. Statistical analysis was performed using GraphPad Prism 6 software (GraphPad Software, Inc.). Normally distributed parameters are presented as the mean ± SD of three independent experimental repeats. Statistical differences between two groups were determined by Student's t-test, and multi-group comparisons were carried out using one-way ANOVA after homogeneity test of variances. Tukey's multiple comparisons test was used after one-way ANOVA. P<0.05 was considered to indicate a statistically significant difference.

Results

Establishment of a mouse model of NA. Airway resistance increased significantly in the NA group after challenge with 25 and 50 mg/ml methacholine, compared with the NC group (P<0.05; Fig. 1A). The enumeration of total cells collected from BALF suggested that NA mice developed airway inflammation, and the numbers of neutrophils and eosinophils
significantly increased in NA, compared with NC (P<0.05; Fig. 1B). Lung histopathology showed intact bronchial lumen and alveolar structure, aligned airway epithelial cells and no infiltration of the inflammatory cells in NC. However, disordered lung structure, widened alveolar septum, broken alveolar wall, and inflammatory cell infiltration (mainly neutrophils) were observed around airways and the interstitial pulmonary in NA (Fig. 1C).

**Th17 cell expression in a mouse model of NA.** Th17 cells and the levels of IL-17 were analyzed using flow cytometry and ELISA, respectively. Th17 cell frequency in the lung and the level of IL-17 in BALF from NA mice were higher than those in NC (Fig. 2A, B and D). The frequency of Th17 cells in the spleens from NA mice was higher than that in NC (P<0.05; Fig. 2C and E).

**IL-7 affects the expression of proliferation markers and anti-apoptotic proteins in Th17 cells in NA mice.** In the NC group, there were no differences in Ki-67 and caspase-3 expression in the presence or absence of IL-7 (Fig. S1). IL-7 promoted the expression of the proliferation marker Ki-67 (P<0.05; Fig. 3A), anti-apoptotic protein Bcl-2 (P<0.05; Fig. 3B) and p-STAT5 (P<0.05; Fig. 3C and D) in Th17 cells from NA mice, compared with untreated cells. However, IL-7 decreased activated caspase-3 expression in NA (P<0.05; Fig. 3A).

**Expression of proliferating and anti-apoptotic proteins is affected by JAK/STAT pathway inhibition in Th17 cells from NA mice.** Compared with NA mice treated with IL-7, STAT5 inhibition decreased the expression of Ki-67 (P<0.01; Fig. 4) and Bcl-2 (P<0.05; Fig. 5) and increased the expression of caspase-3 (P<0.01; Fig. 6) in Th17 cells.

**Discussion**

NA is associated with neutrophil responses not only in severe asthmatics but also in patients with mild and moderate asthma (10). Our previous studies demonstrated that NA mice displayed increased levels of IL-7 and Th17 cell immune responses, as well as IL-17 secreted by Th17 cell-mediated neutrophilic airway inflammation (Jiang et al, unpublished data). However, the mechanisms underlying Th17 cell responses in NA remain unknown. Our previous study demonstrated that sputum supernatant from patients with NA inhibited apoptosis of peripheral blood neutrophils in normal individuals, which suggested a role for the airway micro-environment in the regulation of neutrophil airway inflammation (11). Several previous
studies demonstrated that IL-7 induced the expression of the anti-apoptotic protein Bcl-2 and activated the JAK/STAT signaling pathway, which contributed to T cell survival (6-8). Therefore, it was hypothesized that IL-7 was involved in the Th17 responses seen in NA. In the present study, an NA mouse model was established, in which Th17 cells were affected by
IL-7 and inhibited by suppression of the JAK/STAT pathway. Thus, the IL-7/JAK/STAT signaling pathway was involved in Th17 cell responses in this model of NA.

The results from a previous study on the conventional animal model of asthma sensitized by intraperitoneal injection were inconsistent with those of NA and did not reflect the exact state of airway inflammation and AHR (9). Thus, a mouse model of NA might provide insight into the mechanisms underlying these differences. A previous study demonstrated that allergic sensitization of the airway stimulated robust Th17...
responses, and that neutrophilia was required for AHR (9). In the present study, a mouse model of NA was successfully established by airway delivery of OVA and LPS, based on the previous study by Wilson et al (9). NA mice displayed increased AHR, elevated levels of IL-17 and a high number of neutrophils in BALF. Moreover, numerous inflammatory cells infiltrated around the bronchus and blood vessels. In summary, the current mouse model presented the following features of NA: i) Presence of AHR; ii) accumulation of inflammatory cells in the lung, primarily with increased neutrophils; and iii) high number of neutrophils in BALF.

Accumulating evidence suggests that Th17 cells are involved in the pathogenesis of asthma (9,12), including severe forms of asthma that are refractory to treatment with corticosteroids (13). IL-17 production by Th17 cells is associated with asthma AHR (13), corticosteroid resistance, goblet cell hypersecretion, airway fibrosis and airway remodeling (14). In the present study, NA mice demonstrated strong Th17 responses in the lung and spleen. Moreover, Th17 cell frequency, the level of IL-17 and AHR increased in NA mice when compared with the NC, which was was consistent with a previous study, in which Th17 cells were associated with neutrophilic airway inflammation (15).

IL-7 promotes airway inflammation by activating and maintaining eosinophil survival (16). However, the effects of IL-7 on neutrophils remain unclear. IL-7 is a member of the type I cytokine receptor family and plays a critical role in proliferation, survival and differentiation of T lymphocytes (6,17). Bcl-2 is a crucial anti-apoptotic protein (18), and IL-7 can upregulate Bcl-2 expression (19). Liu et al (20) demonstrated that IL-7 promoted the survival and inhibited Th17 cell apoptosis in auto-immune encephalomyelitis mice. Ki-67 is a nuclear protein associated with cellular proliferation (21), and caspase-3 plays a key role in the execution phase of cell apoptosis (22). The present study was consistent with the findings of Liu et al (20), in which IL-7 administration in NA resulted in increased levels of Ki-67 and Bcl-2, suggesting IL-7 is likely involved in Th17 cell proliferation. Furthermore, lymphocytes treated with caspase-3 inhibitor showed reduced apoptosis (23); IL-7 inhibited caspase-3 activation and reduced T cell apoptosis (5). In the present study, IL-7 administration reduced caspase-3 expression, which suggested that IL-7 was involved in inhibiting Th17 cell apoptosis. These data demonstrated that IL-7 was involved in the response of Th17 cells.

The JAK/STAT signaling pathway is involved in proliferation, differentiation and survival of immune cells (24). Previous studies suggested that the JAK/STAT5 signaling pathway played a role in asthma pathogenesis, and that JAK inhibition significantly antagonized p-STAT5 activation in T cells (25). However, only one previous study suggested that JAK/STAT5 signaling was involved in NA airway inflammation (26). Moreover, the JAK/STAT signaling pathway activated by IL-7 might be the mechanism underlying T cell survival and the development of corticosteroid resistance in asthma (27). The present study demonstrated that IL-7 increased the expression of p-STAT5, and the downstream proteins Ki-67 and Bcl-2 in Th17 cells from NA mice. Moreover, STAT5 inhibition reversed the effect of IL-7 on Ki-67, Bcl-2 and caspase-3 expression in Th17 cells. Thus, IL-7/JAK/STAT5 played a role in the prevalence of Th17 cells in NA mice.

In conclusion, the present study successfully established an NA mouse model by airway delivery of OVA in the presence of LPS. Furthermore, the response of Th17 cells in this model was identified. IL-7 regulated the expression of the proliferation marker Ki-67, anti-apoptotic protein Bcl-2 and pro-apoptotic protein caspase-3, and STAT5 inhibition could reverse this effect. To the best of the authors' knowledge, this is the first study on the contribution of IL-7 to Th17 responses in NA. A limitation of the present study is that the mechanism has not yet been verified in vivo. When assessing the response to IL-7, the lack of a positive control lymphocyte population was another limitation of the present study. Thus, further studies in mice are essential to determine whether IL-7 and JAK/STAT5 pathway blockade are a potential therapeutic approach for NA.

Acknowledgements
Not applicable.

Funding
The present study was supported by International Communication of Guangxi Medical University Graduate Education, Guangxi Natural Science Foundation (grant no. 2018GXNSFAA281256), Innovation Project of Guangxi Graduate Education (grant no. YCBZ2019045), Chen Xiaoping Foundation for the Development of Science and Technology of Hubei Province (grant no. CXPJH1 1900003-17), Guangxi Health Commission Project (grant no. Z20190762) and The Education Foundation of Guangxi (grant no. 2017KY0117).

Availability of data and materials
All data generated or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
XZ performed the experiments and analyzed the data, as well as prepared the manuscript. MZ performed the experiments and interpreted the data, as well as drafted the paper. MJ designed the study and revised the manuscript for important intellectual content. GN contributed to the conception of this study and overall supervision. All authors read and approved the final version.

Ethics approval and consent to participate
The present study was approved by The Ethics Committee of The First Affiliated Hospital of Guangxi Medical University [approval no. 2019(KY-E-035)].

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
References